Generic Name and Formulations:
Epinastine HCl 0.05%; oph soln; contains benzalkonium chloride.
Indications for ELESTAT:
Prevention of itching due to allergic conjunctivitis.
Adults and Children:
<2yrs: not established. ≥2yrs: 1 drop in each eye twice daily.
Remove contact lenses; may reinsert 10 minutes after dosing if eye is not red. Pregnancy (Cat.C). Nursing mothers.
Ocular effects (eg, burning sensation, folliculosis, hyperemia, pruritus), cold symptoms, upper respiratory infections, headache, rhinitis, sinusitis, increased cough, pharyngitis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC